Background Current prophylactic vaccines against human papillomavirus (HPV) target two
of the most oncogenic types, HPV-16 and-18, which contribute to roughly 70% of cervical …

Background Although guidelines for prophylactic human papillomavirus (HPV) vaccination
recommend two doses for girls ages 9–14 years, several studies have demonstrated similar …

Background Human papillomavirus (HPV) vaccines have the potential to reduce cervical
cancer incidence and mortality, particularly in the parts of the developing world that bear the …

Abstract Background In Ethiopia, cervical cancer is the second most common cancer among
women of the reproductive age group. Since 2018, the quadrivalent human papillomavirus …

Abstract Background The World Health Organization (WHO) recommends that the cost
effectiveness of introducing human papillomavirus (HPV) vaccination is considered before …

Objective: To examine the short‐term impact of quadrivalent human papillomavirus
(HPV)(types 6/11/16/18) recombinant vaccination upon HPV disease‐related health‐care …

Eastern Africa has the world's highest cervical cancer incidence and mortality rates. We
used epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to …

Objective As part of the Dose Reduction Immunobridging and Safety Study of Two HPV
Vaccines in Tanzanian Girls (DoRIS; NCT02834637), the current study is one of the first to …

Although no human papillomavirus (HPV) vaccine is indicated for single-dose
administration, some observational evidence suggests that a 1-dose regimen might reduce …

Introduction Human papillomavirus (HPV) vaccination has not been introduced in many
countries in South-Central Asia, including Afghanistan, despite the sub-region having the …